VTRS

Viatris

Halal Rating :
Uncomfortable
Last Price $12.52 Last updated:
Market Cap $14.42b
7D Change -0.87%
1 Year Change 17.56%
Company Overview Use of Interest Company Impact Justification for our Halal Rating Recent News

Company Overview

Industries
  • Manufacturing
  • Pharmaceutical Products
  • Pharmaceutical Preparations
Exchange NASDAQ
Next Earnings Date Nov. 5, 2024

Viatris Inc. is a global pharmaceutical company that develops, manufactures, and distributes generic, branded generic, brand-name, and biosimilar medicines. The company was formed in 2020 through the combination of Mylan and Upjohn, a division of Pfizer. Viatris operates globally, providing access to medicines, advancing sustainable operations, and developing innovative solutions to improve patient health.

The company's portfolio includes products across major therapeutic areas including cardiovascular, infectious disease, oncology, immunology, central nervous system, and diabetes, among others.

Use of Interest

Reporting Date Total Revenue Total Operating Expense Interest Income Interest Expense Interest Income Ratio Interest Expense Ratio
Sept. 30, 2024 $3.75b $3.67b - $145.6m 0.00% 3.97%
June 30, 2024 $3.8b $4.18b - $145.8m 0.00% 3.49%
March 31, 2024 $3.66b $3.6b - $138.4m 0.00% 3.85%

Company Impact

Help us evaluate Viatris's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.

Contribute

Recent News & Updates